Funding for this research was provided by:
PRIN (2017FM74HK)
MISE Proof of Concept
Università degli Studi di Roma Tor Vergata
Article History
Received: 26 May 2021
Accepted: 14 June 2021
First Online: 28 June 2021
Declarations
:
: Viviana Casagrande, Massimo Federici and Rossella Menghini are authors of a patent on the use of Timp3 peptides for treatment of Diabetic Nephropathy.
: The study does not involve any human subjects or animal and does not require disclosure to the rights.
: The study was exempted from the informed consent disclosure as it did not involve any human subjects.